Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Oct
22
Today In Oncology
Claudia Henschke, PhD, MD Finding Lung Cancer in Time
Remote Expert Case Reviews Identify Opportunities to Improve Cancer Care and Reduce Costs
Phase III RT CHARM Trial Supports Shorter Postmastectomy Radiation Therapy After Breast Reconstruction
Experts Call for Better Quality-of-Life Reporting in Adjuvant Cancer Trials
Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo